Tenaya Therapeutics, Inc. (TNYA) — 8-K Filings

8-K Filings (15)

• 8-K Filing — Dec 12, 2025
• Tenaya Therapeutics Files 8-K Report — Dec 11, 2025 Risk: low
  On December 11, 2025, Tenaya Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Stateme
• 8-K Filing — Nov 7, 2025
• Tenaya Therapeutics Files 8-K on Shareholder Votes — May 30, 2025 Risk: low
  Tenaya Therapeutics, Inc. filed an 8-K on May 30, 2025, reporting on matters submitted to a vote of security holders as of May 28, 2025. The filing details the
• Tenaya Therapeutics Faces Delisting Concerns — Apr 18, 2025 Risk: high
  Tenaya Therapeutics, Inc. filed an 8-K on April 18, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the e
• Tenaya Therapeutics Reports Exit/Disposal Costs — Mar 28, 2025 Risk: medium
  On March 27, 2025, Tenaya Therapeutics, Inc. filed an 8-K report detailing costs associated with exit or disposal activities. The filing does not specify the ex
• Tenaya Therapeutics Files 8-K with Material Agreement — Mar 4, 2025 Risk: medium
  On March 3, 2025, Tenaya Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported other ev
• Tenaya Therapeutics Announces Board and Executive Compensation Changes — Feb 7, 2025 Risk: low
  On February 6, 2025, Tenaya Therapeutics, Inc. announced changes to its board of directors and executive compensation. Specifically, Dr. Jeffrey W. Chen was app
• Tenaya Therapeutics Appoints New CMO, Dr. Cook — Jan 28, 2025 Risk: medium
  Tenaya Therapeutics, Inc. announced on January 24, 2025, the departure of its Chief Medical Officer, Dr. Faraz Ali. The company also announced the appointment o
• Tenaya Therapeutics Announces Board and Executive Changes — Dec 17, 2024 Risk: medium
  Tenaya Therapeutics, Inc. announced on December 16, 2024, changes related to its board of directors and executive compensation. Specifically, the company report
• Tenaya Therapeutics Appoints New CMO, Director — Sep 16, 2024 Risk: medium
  Tenaya Therapeutics, Inc. announced on September 12, 2024, the appointment of Dr. Faraz Ali as Chief Medical Officer and the election of Ms. Jennifer L. D. Fox
• Tenaya Therapeutics Announces Board and Executive Changes — Jul 25, 2024 Risk: low
  Tenaya Therapeutics, Inc. announced on July 19, 2024, changes related to its board of directors and executive compensation. Specifically, the company reported t
• Tenaya Therapeutics Appoints New Director, Adjusts Executive Pay — Jun 27, 2024 Risk: low
  Tenaya Therapeutics, Inc. announced on June 25, 2024, changes to its board of directors and executive compensation. Specifically, the company elected Dr. Jeffre
• Tenaya Therapeutics Holds 2024 Annual Meeting — May 31, 2024 Risk: low
  On May 30, 2024, Tenaya Therapeutics, Inc. filed an 8-K report to announce the results of its 2024 Annual Meeting of Stockholders, which took place on May 29, 2
• Tenaya Therapeutics Enters Material Definitive Agreement — Feb 8, 2024 Risk: medium
  Tenaya Therapeutics, Inc. filed an 8-K on February 8, 2024, reporting an "Entry into a Material Definitive Agreement" on February 7, 2024. This filing indicates

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX